Washington, D.C. (May 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on the House Energy and Commerce Committee’s passage of 21st Century Cures legislation:
"PhRMA applauds the House Energy and Commerce Committee and the bipartisan efforts of Chairman Upton and Ranking Member Pallone, Health Subcommittee Chairman Pitts, Health Subcommittee Ranking Member Green and Representative DeGette on the passage of 21st Century Cures legislation to improve the discovery and development of new medicines and treatments for patients. The thoughtful, year-long process that brought countless stakeholders to the table ultimately results in important steps forward for patients.
“Exempting future Food and Drug Administration (FDA) user fees from sequestration is critical to ensuring the FDA is able to fulfill its public health mission by fostering timely patient access to safe and effective new medicines and advancing regulatory science. We are pleased to see this important provision included in the legislation.
"We look forward to bill consideration by the House of Representatives and continued work with the Senate to address these important issues to ensure patients have access to the most innovative treatments."
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: